Hoth Therapeutics has received approval from the University of Texas MD Anderson Cancer Center Institutional Review Board (IRB) to proceed with its First-in-Human Phase 2a clinical trial of HT-001. This milestone marks multiple sites hosting the trial, as Washington University of St Louis previously approved it as well. The randomized, placebo-controlled, parallel Phase 2a dose-ranging study aims to investigate the efficacy, safety, and tolerability of topical HT-001 for treating skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).
Hoth Therapeutics is a patient-focused biopharmaceutical company dedicated to developing innovative treatments that aim to improve patient quality of life. They collaborate with scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options.
Keywords: Hoth Therapeutics, clinical trial, IRB Approval, HT-001, EGFRi